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Abstract
Children with cancer are potentially at a high risk of plasma 25-hydroxyvitamin D (25(OH)D) inadequacy, and despite UK vitamin D
supplementation guidelines their implementation remains inconsistent. Thus, we aimed to investigate 25(OH)D concentration and factors
contributing to 25(OH)D inadequacy in paediatric cancer patients. A prospective cohort study of Scottish children aged <18 years diagnosed
with, and treated for, cancer (patients) between August 2010 and January 2014 was performed, with control data from Scottish healthy children
(controls). Clinical and nutritional data were collected at defined periods up to 24 months. 25(OH)D status was defined by the Royal College of
Paediatrics and Child Health as inadequacy (<50nmol/l: deficiency (<25nmol/l), insufficiency (25–50nmol/l)), sufficiency (51–75nmol/l) and
optimal (>75nmol/l). In all, eighty-two patients (median age 3·9, interquartile ranges (IQR) 1·9–8·8; 56% males) and thirty-five controls (median
age 6·2, IQR 4·8–9·1; 49% males) were recruited. 25(OH)D inadequacy was highly prevalent in the controls (63%; 22/35) and in the patients
(64%; 42/65) at both baseline and during treatment (33–50%). Non-supplemented children had the highest prevalence of 25(OH)D inadequacy
at every stage with 25(OH)D median ranging from 32·0 (IQR 21·0–46·5) to 45·0 (28·0–64·5)nmol/l. Older age at baseline (R −0·46; P< 0·001),
overnutrition (BMI≥ 85th centile) at 3 months (P= 0·005; relative risk= 3·1) and not being supplemented at 6 months (P= 0·04; relative risk= 4·3)
may have contributed to lower plasma 25(OH)D. Paediatric cancer patients are not at a higher risk of 25(OH)D inadequacy than healthy children
at diagnosis; however, prevalence of 25(OH)D inadequacy is still high and non-supplemented children have a higher risk. Appropriate
monitoring and therapeutic supplementation should be implemented.
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Plasma 25-hydroxyvitamin D (25(OH)D) inadequacy (<50nmol/l;
deficiency and insufficiency) is a recognised health problem(1).
Despite vitamin D supplementation guidelines(2,3), their imple-
mentation remains inconsistent(4) and 25(OH)D inadequacy in
healthy children ranges from 14 to 49% worldwide(5). A recent
systematic review reported prevalence of plasma 25(OH)D
deficiency and insufficiency of 41 and 59%, respectively, in
European paediatric cancer patients, higher than healthy children
and paediatric cancer patients from North America (15 and 46%)
and the Middle East (24 and 51%)(6).
Plasma 25(OH)D is primarily obtained from UVB sunlight
through dermal synthesis, but it can also be obtained from the
diet. However, few foods naturally contain vitamin D(7), and in
the UK fortification is rare(8). In high-latitude countries, such as
Scotland(8), populations are at an increased risk of 25(OH)D
inadequacy. Other factors contributing to 25(OH)D inadequacy
in children have been attributed to skin pigmentation, obesity
and age (infants and adolescents)(2,7).
Children treated for cancer experience multiple side effects,
which might affect plasma 25(OH)D. These include phototoxicity,
which requires avoidance of direct sunlight, reduced dietary
intake(9), hepatotoxicity and nephrotoxicity, which may interfere
with the activation of 25(OH)D(10). 25(OH)D inadequacy in
children increases the risk of bone fractures, rickets and slow
growth(11), with a subsequent increased risk of osteoporosis(12).
Most children and adolescents treated for cancer survive into
adulthood(13), but they have an increased risk of developing the
metabolic syndrome, cardiac complications and have a reduced
peak bone mass(13). Despite the importance of vitamin D to
health, the high prevalence of 25(OH)D inadequacy in Europe
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; IQR, interquartile ranges; PTH, parathyroid hormone.
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and the recent call for high-quality population-based longitudinal
cohort studies, there are a few published studies in the UK, and
none in Scotland, investigating plasma 25(OH)D concentration in
paediatric cancer patients(6). To address this clinical question,
we aimed to investigate both plasma 25(OH)D and parathyroid
hormone (PTH) concentrations of paediatric cancer patients at
defined time points for 24 months; compare plasma 25(OH)D
concentration of healthy children with a paediatric cancer cohort
from Scotland; and explore possible factors (age, ethnicity, sex,
seasonality, nutritional status, diagnosis, treatment and the use of
nutritional support) contributing to plasma 25(OH)D inadequacy
at baseline and at 3 and 6 months.
Methods
Study design, population and timeline
A prospective cohort study was conducted. Eligibility criteria were
children aged <18 years, diagnosed with cancer (International
Classification of Childhood Cancer, third edition; ICCC-3)(14) or
Langerhans cell histiocytosis between August 2010 and January
2014 and attending the South East Scotland regional centre (56°N)
for Haematology and Oncology at the Royal Hospital for Sick
Children (RHSC), Edinburgh or Ninewells Hospital, Dundee;
patients were recruited consecutively. We excluded children who
were treated palliatively at any time. Children were monitored for a
maximum period of 24 months and all measurements were
obtained at baseline (newly diagnosed), 3, 6, 9 and 12 months and
every 6 months thereafter. Factors contributing to plasma 25(OH)D
inadequacy were only explored at baseline and at 3 and 6 months
because of the reduced sample size at later stages.
Anonymised control data were obtained from the control
subjects recruited within a case–control study of vitamin D in
children with epilepsy carried out between July 2013 and March
2014 at RHSC. Controls were recruited over an overlapping time
frame, similar representative seasons and regions as the cancer
patients. Consecutive potentially eligible controls attending the
RHSC Emergency Department (which serves SE Scotland) who
were previously healthy, not in extremis nor had an existing
chronic condition (and specifically no epilepsy or other seizure
disorder) and who required blood samples to be taken as part of
their clinical assessment (e.g. child with a fever) were invited to the
epilepsy study. Participants to the epilepsy study along with their
parents gave written informed consent and – where appropriate –
informed assent. Recruitment was completed when the target
sample size for each season was achieved. Advice on vitamin D
supplementation was not provided before sample collection.
Ethical approval for secondary use of the anonymised control data
for comparison with that of the cancer patients in this study,
without the need for additional consent, was given by the South
East Scotland Research Ethics Service. Control data were not
matched for age, sex or BMI; however, samples were matched for
synthesising (1 April–30 September) and non-synthesising periods
(1 October–31 March) for comparative reasons.
Demographics and clinical parameters
Clinical data (diagnosis, treatment protocol and length of treatment)
and demographic data (age, sex, ethnicity and socio-economic
deprivation) were collected from medical notes. Treatment
intensity was classified according to Kazak et al.(15). As a proxy
marker for socio-economic deprivation of individuals, we used
Standard Index of Multiple Deprivation(16).
The paediatric cancer cohort was grouped according to the
wider definition of solid tumours, haematological cancers, brain
tumours and other associated diagnoses.
Data collection
Plasma 25(OH)D, PTH, Ca, phosphate and Mg concentrations
were measured. Plasma 25(OH)D was analysed using liquid
chromatography-tandem MS technique at the Royal Infirmary of
Glasgow and PTH was analysed using the Immulite 2000
Intact PTH technique at the Royal Infirmary of Edinburgh.
The immediate CV (%) for the assays were ≤8·9 and 5·7%,
respectively. Ca, phosphate and Mg were analysed using the
Abbott Architect c8000 at RHSC.
Plasma 25(OH)D concentration was classified as synthesising
(1 April–30 September) and non-synthesising periods
(1 October–31 March). Plasma 25(OH)D status was defined
according to the Royal College of Paediatrics and Child
Health (RCPCH)(2) as deficiency (<25nmol/l), insufficiency
(25–50nmol/l), sufficiency (51–75nmol/l), optimal (>75nmol/l).
Plasma 25(OH)D inadequacy was used when 25(OH)D
concentration was <50nmol/l. Plasma 25(OH)D toxicity was
defined as >175nmol/l (with associated symptoms) and the
PTH reference as 1·7–7·5pmol/l(17).
Height (or length) and weight were measured using standard
procedures. BMI centile was calculated and UK BMI growth
centiles were used. Nutritional status was classified as underweight
(BMI≤2·3th centile), healthy weight (BMI> 2·3rd to <85th centile)
and overweight (BMI≥ 85th centile)(18). Vitamin D intake was
assessed using a 24h multi-pass recall method(19) to establish
patterns of change in vitamin D throughout the study period. This
was analysed in WinDiets® (Univation Ltd 2005) programme(20).
Any nutritional treatment and vitamin D supplementation was
recorded. Nutritional treatment was prescribed according to
subjective global assessment by the multi-disciplinary team and
consisted of enteral±parenteral nutrition (macronutrient) and
micronutrient (vitamin D according to UK RCPCH guidelines(2)
or multivitamins), and a combination of macronutrients and
micronutrients.
This study was granted ethical approval from NHS Scotland
(NHS REC 06-51104-52).
Statistical analyses
The Statistical Package for Social Science (version 19; IBM-SPSS for
Windows Statistics) was used to analyse all data. Descriptive
statistics were used to evaluate the prevalence of plasma 25(OH)D
inadequacy. Comparisons between the paediatric cancer cohort
and the healthy controls were performed using Mann–Whitney
test; correlations between plasma 25(OH)D and the following
variables – Ca, PTH, BMI centile and age – were performed using
Spearman’s correlation. Univariate associations between demo-
graphic data and categorical variables were established by χ2 test.
P<0·05 was considered statistically significant. We followed the
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STROBE guidelines for the presentation of our data(21). No a priori
sample size estimation was performed for this pilot study in a
regional cohort of paediatric cancer patients.
Results
Demographic and clinical characteristics
In all, thirty-three of thirty-five healthy controls and sixty-five of
eighty-two paediatric cancer patients had plasma 25(OH)D
samples available at baseline (Fig. 1). Of the healthy controls, two
(6%) samples were never returned because of laboratory issues.
Demographic and clinical characteristics of the population are
presented in Tables 1 and 2. Sex, ethnicity and socio-economic
status, as well as age at diagnosis, did not statistically differ
between groups. BMI centiles were significantly lower in the
paediatric cancer cohort. A total of twenty-four treatment protocols
were used to treat the paediatric cancer cohort, the median time
follow-up was 312 (interquartile ranges (IQR) 123·5–653·2)d and
22% (n 18) were classified as low risk, 37% (n 30) as medium risk
and 41·5% (n 34) as high risk. The time between diagnosis and
baseline measurements was 15·5 (IQR 10·0–25·0) d and between
the start of cancer treatment and baseline measurements was
9·5 (IQR 6·0–19·5)d. All patients were receiving cancer treatment
when plasma 25(OH)D samples were taken.
Plasma 25-hydroxyvitamin D concentration
At baseline, of the eighty-two paediatric cancer patients, seventeen
(21%) did not have plasma 25(OH)D available because of clinical
reasons (Fig. 1), thirty-four (41%) were obtained during the
synthesising period and thirty-one (38%) during the non-
synthesising period. There was no difference (U (453); P=0·3)
between the synthesising (median 39·0, IQR 30·0–62·0) and
non-synthesising period (median 36, IQR 16·0–61·0) in plasma
25(OH)D concentration in the cancer cohort at any time point,
apart from the 3-month follow-up (Fig. 2). Of the thirty-five con-
trols, nineteen (54%) were obtained during the synthesising period
and twelve (34%) during the non-synthesising period. Plasma
25(OH)D (nmol/l) statistically differed (U (42·5); P=0·003) during
Eligible patients
n 101
Refused to participate
n 19
Baseline
n 82
3 months
n 82
6 months
n 73
9 months
n 65
12 months
n 55
18 months
n 47
24 months
n 35
Samples available
n 65
Samples available
n 56
Samples available
n 34
Samples available
n 30
Samples available
n 24
Samples available
n 18
Samples available
n 12
Reasons for refusal: n 15 too stressful; n 1 parents
felt child was too young; n 1 child refused; n 2
child’s behaviour issues
Reasons: n 11 insufficient sample; n 3 no routine
bloods; n 3 laboratory issues
Reasons for loss to follow-up: n 2 deceased; n 2
palliative; n 1 no appointments; n 2 treatment
outside reach; n 8 insufficient sample; n 16
patient too ill
Reasons for  loss to follow-up: n 3 deceased; n 2
palliative; n 14 treatment outside reach; n 13 no
routine bloods; n 7 laboratory issues
Reasons for  loss to follow-up: n 3 deceased; n 2
palliative; n 8 treatment outside reach; n 1 no
apointments; n 17 no routine bloods; n 4
laboratory issues
Reasons for  loss to follow-up: n 4 deceased; n 2
palliative; n 7 treatment outside reach; n 17 no
due routine bloods; n 1 laboratory issues
Reasons for  loss to follow-up: n 4 deceased; n 2
palliative; n 7 treatment outside reach; n 12 no
routine bloods; n 3 laboratory issues
Reasons for  loss to follow-up: n 4 deceased; n 4
palliative; n 3 missed appointment; n 11 no due
routine bloods; n 1 sample contaminated
Fig. 1. Flow chart showing the sample size at different stages of the study period.
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the non-synthesising (median 26·0, IQR 18·0–46·5) and synthesising
periods (median 56·5, IQR 45·5–78·0). Baseline plasma 25(OH)D of
the cancer cohort did not differ from the healthy controls (P=0·7).
At baseline, prevalence of plasma 25(OH)D inadequacy was
64% (42/65) in cancer patients and 63% (22/35) in healthy
children. There was a higher prevalence of plasma 25(OH)D
deficiency in paediatric cancer patients (n 19; 29%) in comparison
with healthy children (n 8; 22%), but this was not statistically
significant (P=0·2; χ2 test). In the cancer cohort, prevalence of
plasma 25(OH)D inadequacy ranged between 33 and 50%
throughout the study period (Fig. 3). Patients with solid tumours
had the highest prevalence of 25(OH)D inadequacy (34%)
followed by haematological malignancies (26%) at both baseline
(Table 2) and at all time points (online Supplementary Table S1).
At baseline, of thirty-two solid tumour patients 37·5% (n 12) were
deficient and 31·2% (n 10) were insufficient and of twenty-six
haemalogical malignancy patients 19·2% (n 5) were deficient and
46·1% (n 12) were insufficient (Table 2).
Nutritional support was prescribed to 26% (21/82) of
paediatric cancer patients at baseline, of which 14/82 (17%) were
on macronutrients (enteral±parenteral nutrition) and 7/82 (8%)
were on both macronutrients (enteral±parenteral nutrition) and
micronutrients. The median time between the start of nutritional
support and baseline was 8 (IQR 0–23) d. In all, 80% (66/82) of
cancer patients received vitamin D from one or more forms of
nutritional support for several days or weeks during the study
period. Of these, 39/82 received macronutrient supplementation
providing 292 (IQR 128–332) IU/d, 48/82 (58%) received both
micronutrient and macronutrient supplementation providing 464
(IQR 440–664) IU/d and 21/82 (26%) received macronutrient
only and micronutrient (±macronutrient) supplementation. The
vitamin D intake from diet alone was 68 (IQR 24–76) IU/d and
supplementation of vitamin D ranged from 400 IU/d to 20 000 IU
single dose of vitamin D during the study period.
Paediatric cancer patients who were not supplemented had the
lowest plasma 25(OH)D. The prevalence of plasma 25(OH)D
Table 1. Characteristics of the paediatric cancer population and the healthy controls
(Medians and interquartile ranges (IQR); numbers and percentages)
Paediatric cancer cohort Controls
Baseline characteristics Median IQR Median IQR P
Total sample (n) 82 35
Age 3·9 1·9–8·8 6·2 4·8–9·1 0·1*
BMI centile 50 19·0–84·5 60·5 43·7–89·5 0·003*
Plasma 25(OH)D 38·0 21·0–61·0 37·5 23·0–58·0 0·7*
n % n %
Sex 0·5†
Male 46 56·1 17 48·6
Female 36 43·9 18 51·4
Ethnicity 0·6†
White 80 97·6 33 94·3
Non-white 2 2·4 2 5·7
SES 0·06†
I 15 18·3 3 8·6
II 13 15·8 8 22·9
III 15 18·3 5 14·3
IV 24 29·3 5 14·3
V 15 18·3 14 40·0
Haematological malignancies 35 43 – –
ALL 29 35
AML 3 4
CML 2 2
HLH 1 1
Solid tumours 39 47
Lymphomas 10 12
Neuroblastoma 6 7 – –
Retinoblastoma 2 2 – –
Renal tumours 6 7 – –
Hepatic tumours 1 1 – –
Malignant bone tumours 4 5 – –
Soft tissue sarcoma 5 6 – –
Germ cell tumours 1 1 – –
Malignant epithelial neoplasm 4 5 – –
Other unspecified malignancy 0 0 – –
Other associated diagnoses 3 4 – –
LCH 3 4
Brain tumours–CNS tumours 5 6
SES, socio-economic status; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; HLH,
hemophagocytic lymphohistiocytosis; LCH, Langerhans cell histiocytosis; CNS, central nervous system.
* Mann–Whitney test.
† χ2 Test. SIMD: Standard Index of Multiple Deprivation presented as a quintile where ‘I’ denotes the most deprived and ‘V’ the least deprived.
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inadequacy stratified by nutritional support and stages of disease is
presented in Table 3. This was highest in children who did not
receive supplementation ranging from 32·0 (IQR 21·0–46·5) nmol/l
at 18 months to 45·0 (IQR 28·0–64·5)nmol/l at 24 months.
In contrast, paediatric cancer patients supplemented with micro-
nutrients (±macronutrient) had the lowest prevalence of plasma
25(OH)D inadequacy and the highest plasma 25(OH)D at most
stages ranging from 78·0 (IQR 49·2–134·5)nmol/l at 6 months to
82·0 (IQR 57·0–128·5)nmol/l at 12 months. This was followed by
children supplemented with macronutrients only, which ranged
from 43·0 (29·2–75·7)nmol/l at baseline to 79·0 (IQR 49·0–
93·0) nmol/l at 6 months. A considerable number of patients
in the macronutrient subgroup had already received micronutrient
supplementation. Of the seven patients who were on macro-
nutrient support at 6 months, all of them had received micro-
nutrient supplementation previously. Similarly, 2/5 (40%) patients
on macronutrient support at 12 months and 1/2 (50%) patients at
18 months had received micronutrient supplementation in the
previous follow-up. Moreover, micronutrient supplementation
was significantly associated with a lower prevalence of plasma
25(OH)D inadequacy (Fisher’s exact test; P = 0·04; relative risk
0·27; 95% CI 0·04, 1·8) at 6 months. Three patients reached
plasma 25(OH)D concentration of >175nmol/l(17) following a
single high dose (20000 IU/d) of vitamin D.
Plasma 25(OH)D did not correlate with plasma Ca, phosphate,
Mg and PTH at any stage in the cancer cohort; however, PTH and
plasma 25(OH)D concentration correlated in the healthy controls
(r 0·6; P<0·001).
Factors contributing to 25-hydroxyvitamin D inadequacy
concentration at baseline and at 3 and 6 months of
treatment
Age negatively correlated with plasma 25(OH)D concentration in
paediatric cancer patients (r −0·46; P< 0·001), only at baseline,
and in healthy children (r −0·42; P< 0·02), whereby older childrenTa
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Fig. 2. Plasma 25-hydroxyvitamin D (25(OH)D) with data stratified according to
seasonal variation. Values are means, with their standard deviations represented
by vertical bars (* P<0·05), independent t test used to compare 25(OH)D
concentration between synthesising ( , 1 April–30 September) and non-
synthesising periods ( , 1 October–31 March).
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had lower plasma 25(OH)D concentration. Although BMI centile
was not significantly correlated with plasma 25(OH)D concentra-
tion in the paediatric cancer cohort at baseline (r −0·2; P=0·08),
3 months (r −0·2; P=0·2) and 6 months (r −0·2; P= 0·3), and in
the healthy controls (r −0·3; P=0·3), overnourished paediatric
cancer patients were more likely to have higher prevalence of
plasma 25(OH)D inadequacy (χ2 test (8·3); df (1); P=0·005;
relative risk 3·1; 95% CI 1·4, 14·0) at 3 months than healthy and
undernourished children with cancer, regardless of whether the
patients were on nutritional supplementation. Non-supplemented
children were more likely to have inadequate plasma 25(OH)D
concentration (relative risk 4·3; 95% CI 1·1, 4·7) at 6 months
(Fisher’s exact test; P= 0·04) compared with those supplemented
with micronutrients.
None of the following categorical variables were significantly
associated with plasma 25(OH)D status and paediatric cancer
patients at any stage: treatment risk, diagnostic criteria, ethnicity
and sex.
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Fig. 3. Plasma 25-hydroxyvitamin D (25(OH)D) concentration ( , deficiency<25nmol/l, left) and prevalence of 25(OH)D deficiency and insufficiency ( , insufficiency
25–50nmol/l, right) at different stages of the study period. Values are means, with their standard deviations represented by vertical bars (left).
Table 3. Prevalence of plasma 25-hydroxyvitamin D (25(OH)D) inadequacy with data stratified by nutritional support and at different stages of the disease†
(Numbers and percentages; medians and interquartile ranges (IQR))
Deficiency Insufficiency Sufficiency Optimal
Timeline Nutritional support n n % n % n % n % Median IQR
Baseline (n 65) None 44 16 25 15 23 11 17 2 3 34·0 20·2–52·7
Macronutrients 14 2 3 6 9 3 5 3 5 43·0 29·2–75·7
Micronutrients±macronutrients 7 1 1 1 1 3 5 2 3 71·0 41·0–97·0
3 months (n 55) None 25 4 7 11 20 6 11 4 7 45·0 32·0–56·0
Macronutrients 9 1 2 1 2 4 7 3 5 67·0 48·0–76·5
Micronutrients±macronutrients 20 1 2 6 11 7 13 6 11 67·5 38·0–87·7
6 months (n 34) None 9 3 9 2 6 4 12 0 0 45·0 16·5–68·0
Macronutrients 7 0 0 2 6 1 3 4 12 79·0 49·0–93·0
Micronutrients±macronutrients 18 1 3 3 9 4 12 10 29 78·0 49·2–134·5
9 months (n 30) None 16 1 3 7 23 6 20 2 7 45·0 31·0–61·0
Macronutrients 8 1 3 2 7 2 7 3 10 59·0 35·5–84·25
Micronutrients±macronutrients 6 0 0 0 2 7 4 13 77·5 66·5–101·0
12 months (n 24) None 11 3 12 4 17 1 4 3 12 36·0 24·5–79·0
Macronutrients 5 0 0 1 4 4 17 0 0 63·0 51·0–63·0
Micronutrients±macronutrients 8 0 0 0 0 5 21 3 12 82·0 57·0–128·5
18 months (n 18) None 12 3 17 7 39 2 11 0 0 32·0 21–46·5
Macronutrients 2 0 0 0 0 1 6 1 6 67·5 56·0
Micronutrients±macronutrients 3 0 0 0 0 3 17 0 0 64·0 42·7–134·0
24 months (n 12) None 5 1 8 2 17 2 17 0 0 45·0 28·0–64·5
Macronutrients 0 0 0 0 0 0 0 0 0
Micronutrients±macronutrients 7 2 17 1 8 0 0 4 33 67·0 23·7–106·2
OAD, other associated diagnoses.
† 25(OH)D reference ranges: deficiency <25nmol/l, insufficiency 25–50nmol/l, sufficiency 51–75nmol/l, optimal >75nmol/l, 25(OH)D inadequacy (<50nmol/l).
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Discussion
This is the first study investigating plasma 25(OH)D concentration
at diagnosis and during treatment in paediatric cancer patients
from Scotland. Our results show a high prevalence of plasma
25(OH)D inadequacy during the study period. Plasma 25(OH)D
concentration in paediatric cancer patients and age-matched
healthy controls were similar; however, our paediatric cancer
cohort showed no seasonal variation. Children diagnosed with
solid tumours exhibited the lowest plasma 25(OH)D concentration
and the only effective method to achieve optimal plasma
25(OH)D concentration was by supplementing with vitamin D.
Only three factors, and each at 1 time point only, contributed to
plasma 25(OH)D inadequacy: older age was the only factor at
baseline, overnutrition at 3 months and not being supplemented at
6 months during treatment.
Prevalence of plasma 25-hydroxyvitamin D
In contrast to North England(22) but in agreement with a recent
Scottish small study(23), our study shows that plasma 25(OH)D
concentration in newly diagnosed paediatric cancer patients
and healthy children were comparable, suggesting that patients
from Scotland are not at a higher risk of plasma 25(OH)D
inadequacy than healthy children at diagnosis. However, these
concentrations are lower than those reported in paediatric
cancer patients from Europe(6). Of note, 11% of paediatric
cancer patients were on vitamin D supplementation at baseline,
which may have contributed to higher plasma 25(OH)D
concentration at this stage. In addition, there was a higher
representation of winter samples in the healthy controls than
the paediatric cancer cohort (30 v. 43%), which might have
contributed to the unexpectedly higher prevalence of vitamin D
inadequacy in the healthy controls.
Optimal plasma 25(OH)D in children is essential to allow optimal
growth, Ca homoeostasis and skeletal development(3). Children
treated for cancer may have impaired growth velocity during
treatment(24), which can also be exacerbated by vitamin D inade-
quacy. Current UK guidelines on vitamin D are aimed at healthy
children and stipulate that children under 5 years of age should be
supplemented with 7·5–10µg/d (300–400 IU) of vitamin D(2). We
have clearly established that most cancer patients who were not
supplemented were either deficient or insufficient, or eventually
became deficient, as shown by the high prevalence of plasma
25(OH)D inadequacy (33–50%). Furthermore, macronutrient
supplementation alone prevented plasma 25(OH)D inadequacy,
but patients rarely reached optimal concentration, suggesting that
macronutrient supplementation, which is fortified with vitamin D,
does not meet the requirements for vitamin D in this population.
Finally, vitamin D supplementation taken in the form of
multivitamins or as therapeutic supplementation was essential to
achieve optimal 25(OH)D concentration in all paediatric cancer
patients. Remarkably, we found that older children were at a
higher risk of plasma 25(OH)D inadequacy at baseline and
therefore would also require supplementation, which is not stipu-
lated in the RCPCH guidelines(2). However, it is important to
note that three patients on single high-dose (20000 IU) vitamin D
supplementation reached 25(OH)D>175nmol/l concentration(17).
Therefore, we recommend vitamin D supplementation for
all paediatric cancer patients, but emphasise the need for close
monitoring to avoid potential toxicity.
Unlike healthy children, our paediatric cancer cohort did not
show any seasonal variation in plasma 25(OH)D concentration.
These findings are supported by a study performed in survivors
of childhood cancer from the USA (latitude 34°N)(25) but
contrasts with two studies(22,26): one performed in North
England (latitude 54·9°N) during and after therapy(22) and the
other performed in Israel (latitude 31°N) in paediatric cancer
patients during therapy(26). Therefore, we hypothesise that
Scottish paediatric cancer patients are not exposed to enough
sunlight during the summer months, probably becase of the
multiple treatment side effects(24,25), and that diet alone is
insufficient to replenish plasma 25(OH)D stores.
Stratification of the data by diagnosis revealed results consistent
with a recent systematic review(6) and a large study (n 2198)
performed in the adult oncology population from USA. Patients
diagnosed with solid tumours had prevalence of plasma 25(OH)D
inadequacy of 71 and 75%, respectively; our study showed that
children diagnosed with solid tumours exhibited the highest
prevalence of plasma 25(OH)D inadequacy (69%; deficiency
37·5% and insufficiency 31·2%) at diagnosis. However, our study
also showed high prevalence of plasma 25(OH)D inadequacy in
the haematological malignancy group (65%; deficiency 19·2% and
insufficiency 46·1%) at diagnosis, which contrasts with findings
from elsewhere(6,25). Although others have reported similar
prevalence of vitamin D inadequacy in Canadian children
diagnosed with haematological malignancies(27,28), the measured
vitamin D was 1,25-dihydroxyvitamin D (1,25(OH)2D), which is
not equivalent to plasma 25(OH)D. Despite supplementation with
macronutrients and micronutrients, prevalence of 25(OH)D
inadequacy remained high during treatment for solid tumours
and haematological malignancies, highlighting the need for more
rigorous monitoring at all stages.
In line with recent evidence(6,22), our study found a relationship
between PTH and plasma 25(OH)D in healthy controls, but not in
paediatric cancer patients. Although in health PTH measured
alongside plasma 25(OH)D is considered the most sensitive
physiological measure of plasma 25(OH)D status and bone
homoeostasis(29), our study suggests that there might be other
factors influencing their relationship. We were unable to investi-
gate this because of the relatively small sample; however, it has
been attributed to the type of cancer and the different treatments,
including chemotherapy and corticosteroids, which can lead to
nephrotoxicity and hepatotoxicity, in turn interfering with the
25(OH)D, 1,25(OH)2D and PTH metabolism(10,30). Furthermore,
a stronger relationship between plasma PTH and 25(OH)D
develops with age(31), which might have affected our results, as
the controls were slightly older.
Factors contributing to reduced plasma 25-hydroxyvitamin D
concentration at baseline and at 3 and 6 months
Consistent with a meta-analysis(6), older age was associated
with reduced plasma 25(OH)D concentration in paediatric
cancer patients at baseline. This association was also found in
1932 R. Revuelta Iniesta et al.
http://dx.doi.org/10.1017/S0007114516004074
Downloaded from http:/www.cambridge.org/core. Edinburgh College of Art, on 04 Jan 2017 at 13:48:40, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
our healthy controls, in line with a study performed in healthy
children from the USA(32), which could reflect the widespread
issue of vitamin D. Teenagers tend to eat less vitamin-D-rich
foods, especially fortified foods, and spend less time playing
outdoors than younger children(33). In addition, the high levels
of vitamin D inadequacy during treatment could have been
attributed to the fact that patients were supplemented with a
very low dose of vitamin D (440–664 IU). A higher dose of
600 IU is recommended for all paediatric patients (including
infants), whereas therapeutic doses are age dependent and all
doses are over 1000 IU/d(3,17). Alongside infancy, puberty is
accompanied by a rapid period of growth, and appropriate
plasma 25(OH)D concentration is essential to allow for optimal
growth(34); thus, this population should be targeted and
appropriate doses should be prescribed to all patients.
In contrast with other studies investigating factors contributing
to plasma 25(OH)D inadequacy in paediatric cancer patients(23,26),
our results showed that(7) like healthy individuals, overnourished
children maybe more likely to have plasma 25(OH)D inadequacy
following 3 months of treatment, and this was regardless of
nutritional support. An inverse relationship between high BMI and
plasma 25(OH)D in the healthy population is well established(7),
which has been attributed to a reduction in plasma 25(OH)D
availability due to the sequestration of vitamin D by adipose tis-
sue(35). Overweight children require higher doses of chemother-
apy and glucocorticoids than normal-weight or undernourished
children. In addition, cancer treatments tend to be most intense
during the first 3–6 months post diagnosis. Chemotherapy agents
commonly used in cancer treatment can cause hepatotoxicity and
nephrotoxicity and thus inhibit the activation of vitamin D(27),
whereas glucocorticoids stimulate vitamin D catabolism and can
increase the risk of vitamin D deficiency(27). Therefore, higher
doses of chemotherapy agents and glucocorticoids may explain
this association between overnourished patients and lower
25(OH)D concentration
Limitations of the study and future research
The reduced sample size at later stages of the study precluded
considering factors associated with plasma 25(OH)D at later
stages of treatment. Some cancer patients were already on
nutritional support at baseline, which could potentially have
affected plasma 25(OH)D concentration. It should be noted that
although age did not statistically differ between the controls and
the cancer cohort, the controls were slightly older. In addition,
the higher proportion of samples obtained from the non-
synthesising period in the controls may have distorted the high
plasma 25(OH)D inadequacy reported. Finally, there were only
two non-Caucasian patients (dark skin) in both groups, which
could explain why lower plasma 25(OH)D concentration was
not associated with ethnicity. Future research should include
large multicentre epidemiological studies that are better able to
identify factors contributing to plasma 25(OH)D inadequacy in
the different types of cancer during treatment, as well as
randomised controlled trials in which the effects of vitamin D
supplementation on clinical outcome, particularly bone mass
density, are warranted.
Conclusion
We have highlighted that Scottish paediatric cancer patients have a
high prevalence of plasma 25(OH)D inadequacy at diagnosis and
during treatment and that older age, not being supplemented and
possibly being overnourished potentially contribute to inadequacy.
Importantly, we recommend vitamin D supplementation to all
paediatric cancer patients given that macronutrient supplementa-
tion alone prevented further 25(OH)D inadequacy, but rarely
produced optimal concentration, and high longitudinal inadequacy
rates continued throughout the study.
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